8-K: Glucotrack Faces Nasdaq Delisting, Eyes OTC Markets

Glucotrack, Inc. has received notice from Nasdaq of its intent to delist the company's securities due to failure to meet the minimum bid price requirement, with trading suspension set for October 30, 2026.

Summary

• Glucotrack, Inc. has been notified by The Nasdaq Stock Market LLC (Nasdaq) that its securities will be delisted.
• The delisting is due to the company's failure to comply with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00.
• Despite a previous exception granted by a Nasdaq Hearings Panel, the company's closing bid price of $0.87 on October 14, 2026, meant it did not meet the exception's conditions.
• Trading of Glucotrack's common stock on Nasdaq will be suspended starting October 30, 2026.
• The company anticipates Nasdaq will file a Form 25 to formally delist and deregister the securities.
• Glucotrack plans for its shares to be quoted on the OTC Markets Group, Inc. (OTC), specifically aiming for the OTCID Market (OTCID).

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development due to the impending delisting from Nasdaq, indicating severe financial distress and a loss of investor confidence.

Negatives

• The company's securities are being delisted from The Nasdaq Stock Market.
• The reason for delisting is the failure to maintain a minimum bid price of $1.00.
• Trading suspension on Nasdaq is scheduled to begin on October 30, 2026.
• The company's closing bid price was $0.87 on October 14, 2026, failing to meet Nasdaq's exception terms.

Risks

• Continued failure to meet minimum bid price requirements could lead to further trading venue restrictions.
• The transition to OTC markets may result in reduced liquidity and investor interest.
• The company's financial health is under scrutiny, as evidenced by the delisting notice.

Future Outlook

The company expects its shares of common stock to be quoted by OTC Markets Group, Inc. (OTC) upon suspension from Nasdaq and intends to apply for trading on the OTCID Market (OTCID).

Management Comments

• The Company expects and plans for its shares of common stock to be quoted by the OTC Markets Group, Inc. (OTC) upon being suspended from trading on Nasdaq and intends to submit an application to have its securities traded on the OTCID Market (OTCID) of OTC.

Industry Context

StockSavvy.ai notes that delisting from a major exchange like Nasdaq due to failure to meet listing standards, such as minimum bid price, is a significant negative signal. It often reflects underlying business challenges and can severely impact a company's ability to attract capital and maintain investor confidence, pushing it to less regulated and less liquid markets.

Stakeholder Impact

• Shareholders: Potential decrease in share liquidity, reduced investor confidence, and possible decline in share value due to trading on OTC markets.
• Creditors: Increased risk associated with the company's financial stability and ability to meet obligations.

Next Steps

• Trading suspension on Nasdaq effective October 30, 2026.
• Nasdaq to file Form 25 with the SEC for delisting and deregistration.
• Company shares to be quoted on OTC Markets Group, Inc. (OTC).
• Application to have securities traded on the OTCID Market (OTCID) of OTC.

Key Dates

Recommendation

The impending delisting from Nasdaq due to failure to meet listing requirements is a strong indicator of severe financial distress and a significant loss of market confidence. The move to OTC markets typically results in lower liquidity and investor scrutiny, making it a highly unfavorable development for shareholders.

Keywords

Delisting, Nasdaq, OTC Markets, Bid Price Rule, Securities Suspension, Form 8-K, Glucotrack